Drug Approval | January 20, 2022
VFMCRP receives EU approval for Tavneos for the treatment of ANCA-associated vasculitis
First launches expected in H1 2022
First launches expected in H1 2022
They will commercialize molnupiravir in the international markets
This surpasses the number of approvals supported in 2020
Health experts of the country have pointed out that the benefits of the drug outweigh the potential risks it may have in the case of high-risk patients
Novavax' vaccine has received authorizations of the vaccine in over 170 countries
Earlier last week the U.S. FDA had also shortened the time to receive a Pfizer booster shot from six months to five months for everyone 12 and older
The drug is priced at Rs 2000 for a course of 40 tablets
First emergency use authorization in the United States for a Covid-19 vaccine booster in adolescents 12 through 15 years of age
Emergency Use Authorisation application request to be submitted following one month required by FDA EUA guidance
ASC10 is an oral direct-acting antiviral drug candidate targeting RNA dependent RNA polymerase (RdRp) to treat SARS-CoV-2 infection
Subscribe To Our Newsletter & Stay Updated
